menu
    • menu

    Company profile for Assia Chemical Industries Ltd

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Teva-Tech is the fastest growing manufacturing facility of TAPI. Most of the new chemically synthesized products produced by TAPI are manufactured at this location, or will be in the future. Many dedicated, high volume manufacturing areas can be found at Teva-Tech. The leading products produced at Teva-Tech include Gabapentin, Furosemide, Azithromycin, Clarithromycin, Venlafaxine. In addition, Teva-Tech produces certain niche ...
    Teva-Tech is the fastest growing manufacturing facility of TAPI. Most of the new chemically synthesized products produced by TAPI are manufactured at this location, or will be in the future. Many dedicated, high volume manufacturing areas can be found at Teva-Tech. The leading products produced at Teva-Tech include Gabapentin, Furosemide, Azithromycin, Clarithromycin, Venlafaxine. In addition, Teva-Tech produces certain niche products, using novel technologies that are difficult to develop. Examples of these products include peptides such as Desmopressin and Vitamin D derivatives such as Calcitriol, Alpha D3 and Calcipotriene.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Assia Chemical Industries LtdIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    Neot-Hovav Eco-Industrial Park, Emek Sara P.O Box 2049 Be'er Sheva 8412316
    Telephone
    Telephone
    +972-39255519
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.teva.co.il/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Not Confirmed

    envelop Contact Supplier

    CPhI China

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 1144

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaYour Biologic Therapeutic Stabilization, Protection & Delivery PartnerYour Biologic Therapeutic Stabilization, Protection & Delivery Partner

    Your Biologic Therapeutic Stabilization, Protection & Delivery Partner
    Your Biologic Therapeutic Stabilization, Protection & Delivery Partner

    reelYour Biologic Therapeutic Stabilization, Protection & Delivery Partner

    This PharmaReel highlights Pfanstiehl's portfolio, featuring highest-purity, low-endotoxin injectable-grade excipients, generic APIs and intermediates, HPAPIs, and modified carbohydrates. The company provides API custom synthesis and ADC linker manufacturing services, all backed by USFDA certification.

    Impressions: 453

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    The pharmaceutical excipients market saw significant strategic consolidations, technological developments, and regulatory adaptations in 2025. Globally, the pharmaceutical excipients sector is growing at a compound annual growth rate of 6.6 percent, and was valued at US$ 8.85 billion in 2024. It is projected to reach US$ 14.77 billion by 2032.This year, the sector is witnessing technological advancements, regulatory evolution, and strategic business realignments. North America continues to dominate the global excipients landscape, with a 39.8 percent market share. The Asia-Pacific region is the fastest-growing segment with a substantial 30.4 percent market share, driven by increasing investments in pharmaceutical manufacturing, growing demand for cost-effective drugs, and rising healthcare expenditure across developing economies.Major excipient providers include BASF, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, DuPont, Evonik, Seqens, Actylis, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Kewpie Corporation, Boai NKY Pharmaceuticals, ICE Pharma, Roquette, Nanjing Well Pharmaceutical, Minakem, Ashland Global, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Roquette restructures after buying IFF Pharma; Colorcon partners ASHA CelluloseIn May, Roquette completed its acquisition of IFF Pharma Solutions. Valued at up to US$ 2.85 billion in enterprise value, this transaction represents a major consolidation in the pharmaceutical excipients market. The acquisition significantly enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide. Roquette announced a comprehensive, new organizational structure following the acquisition, indicating the company’s commitment to integrate IFF Pharma Solutions’ capabilities seamlessly into its existing operations. This consolidation creates a more robust platform for addressing the growing demand for specialized excipients in complex drug formulations, particularly as the industry moves towards more personalized approaches to medicines.So far, the year has also witnessed some strategic alliances, such as Colorcon’s partnership with ASHA Cellulose. As part of the deal, Colorcon will become the exclusive representative for two ASHA products — ASHACEL and ASHAKOTE — throughout Europe, the Middle East, Africa, Northeast Asia and Southeast Asia.Brenntag Specialties has announced an exclusive distribution agreement with MEGGLE Excipients to expand market reach. This collaboration makes available a broad portfolio of over 30 high-quality lactose-based excipients for various applications in the pharmaceutical industries across the Netherlands, Belgium, Norway, Finland, and Sweden.The portfolio’s versatility offers optimal solutions for a wide range of pharmaceutical applications, including tableting through both granulation and direct compression, powder preparations, and dry powder inhalation. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)WHO, FDA drive new standards with GMP guidelines; Pfanstiehl launches injectable-grade glycineIn March, the World Health Organization had put out a publication titled “Good Manufacturing Practices for Excipients used in Pharmaceutical Products.” WHO’s excipient GMP guideline emphasizes modern quality management principles, comprehensive risk assessment protocols, and supplier qualification procedures for excipients across all stages of production, storage, and distribution.Meanwhile, the US Food and Drug Administration (FDA) has proposed amendments to the Food, Drug, and Cosmetic Act as part of its FY 2025 legislative proposals, specifically targeting supply chain transparency for high-risk excipients. The FDA proposal would require certain excipients designated as high-risk to carry labeling that identifies the original manufacturer’s name and address. This initiative addresses what FDA has identified as a lack of transparency in excipient supply chains.In April, IFF Pharma Solutions launched Low Nitrite METHOCEL hydroxypropyl methylcellulose (HPMC). This innovative product is specifically designed to reduce the risk of nitrosamine formation in finished pharmaceutical dosages, addressing one of the most pressing concerns in contemporary pharmaceutical manufacturing.Pfanstiehl, a global leader in high-purity excipient manufacturing, announced the launch of its High Purity Low Endotoxin Low Metals (HPLE-LM) injectable-grade glycine. This multi-compendial glycine is specifically engineered for use in biologics, vaccines, and the downstream purification of monoclonal antibodies (mAbs). Manufactured under ICH-Q7 cGMP regulations at Pfanstiehl’s advanced facility in Waukegan, Illinois, the product meets stringent global pharmacopeial standards. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Shin-Etsu Chemical invests in Japan, Germany to expand cellulose productionIn March, Shin-Etsu Chemical announced investments in pharmaceutical cellulose business operations in Japan and Europe, thereby showing significant commitment to market expansion. The company is making substantial investments at two key bases: the subsidiary SE Tylose GmbH in Germany, and the Naoetsu Plant in Joetsu, Japan. In Germany, a new production facility for the pharmaceutical excipient L-HPC will be built adjacent to the existing facility, creating a dual base with the Naoetsu Plant. The excipients market in 2025 has seen innovation in functional applications. Research on BENEO’s Palatinose as a bedtime drink shows that it improves aspects of sleep and represents an innovative approach to excipient functionality. Palatinose is a naturally sourced, smart carbohydrate that provides full carbohydrate energy in a more balanced way, thanks to its low-glycemic profile.Gangwal Healthcare, with its EXCiPACT-certified GMP facilities and a robust portfolio of co-processed excipients like ProBlend, Starlose, and Microlose, is actively contributing to the pharmaceutical industry’s demand for functional excipients. The company also offers cellulose-based excipients such as Solvostar (Sodium Starch Glycolate) and Sallyso (Croscarmellose Sodium), designed to improve tablet disintegration and drug release profiles in oral solid dosage forms.Evonik announced a partnership with South Korea–based CDMO ST Pharm to expand its RNA and nucleic acid delivery services. This collaboration enables Evonik to integrate customized nucleic acids from ST Pharm seamlessly with its lipid and lipid nanoparticle (LNP) development and fill-and-finish services. This streamlined approach means that pharmaceutical companies can reduce complexity and increase speed-to-market for nucleic acid therapeutics. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Our viewThe pharmaceutical excipients market in 2025 is being shaped by several key trends including the development of multifunctional excipients that can simultaneously improve solubility, bioavailability, and control drug release in increasingly complex formulations.Moreover, the expanding generic medicines market is creating demand for cost-effective, versatile excipients. The growing importance of biologics and biosimilars is driving innovation in specialized excipients designed to maintain the stability and efficacy of these complex therapeutic products throughout their lifecycle. And nanotechnology continues to enable advanced nano-excipients for enhanced drug delivery and efficacy.In addition to these trends, we also notice a shift towards natural and plant-based excipients that is driven by sustainability concerns and potential biocompatibility benefits. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1652

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks

    #PharmaFlow by PHARMACOMPASS
    29 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Pharma's Generics Tiopronin Receives Approval in US
    Teva Pharma's Generics Tiopronin Receives Approval in US

    22 Jul 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216456

    FDA
    22 Jul 2024
    Share Share
    U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
    U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

    23 Apr 2024

    // Blake Brittain REUTERS

    https://www.reuters.com/legal/us-supreme-court-rejects-vanda-pharmaceuticals-case-over-sleep-drug-patents-2024-04-22/

    Blake Brittain REUTERS
    23 Apr 2024
    Share Share
    Teva, like Hikma, accuses Amarin of hoarding Vascepa ingredient
    Teva, like Hikma, accuses Amarin of hoarding Vascepa ingredient

    30 Mar 2024

    // Fraiser Kansteiner FIERCE PHARMA

    https://www.fiercepharma.com/pharma/teva-follows-suit-after-hikmas-2023-complaint-arguing-amarin-locked-drug-ingredient-supply

    Fraiser Kansteiner FIERCE PHARMA
    30 Mar 2024
    Share Share
    Teva reports revenue increase, says it will sell API business
    Teva reports revenue increase, says it will sell API business

    01 Feb 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/continuing-its-transformation-teva-confirms-intent-sell-api-business

    Kevin Dunleavy FIERCE PHARMA
    01 Feb 2024
    Share Share
    Accused of complicity in opioid crisis, Teva launches nasal spray
    Accused of complicity in opioid crisis, Teva launches nasal spray

    25 Dec 2021

    // TIMESOFISRAEL

    https://www.timesofisrael.com/accused-of-complicity-in-opioid-crisis-teva-launches-nasal-spray-to-treat-overdose/

    TIMESOFISRAEL
    25 Dec 2021
    Share Share
    Teva's Ajovy can't find solid win against oral migraine rivals
    Teva's Ajovy can't find solid win against oral migraine rivals

    09 Sep 2021

    // N. H. Dunn FIERCEPHARMA

    https://www.fiercepharma.com/pharma/teva-trailing-cgrp-rivals-migraine-can-t-find-a-win-ajovy-analysis-versus-biohaven-and

    N. H. Dunn FIERCEPHARMA
    09 Sep 2021
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Assoc...

    Details:

    AUSTEDO (deutetrabenazine) is the first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia (TD) in adults and for the treatment of chorea associated with Huntington’s disease.


    Lead Product(s): Deutetrabenazine

    Therapeutic Area: Musculoskeletal Brand Name: Austedo

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 18, 2022

    blank

    01

    Assia Chemical Industries Ltd

    Israel
    arrow
    IOPC
    Not Confirmed

    Assia Chemical Industries Ltd

    Israel
    arrow
    IOPC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Deutetrabenazine

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deute...

    Details : AUSTEDO (deutetrabenazine) is the first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia (TD) in adults and for the treatment of chorea associated with ...

    Product Name : Austedo

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 18, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respirator...

    Details:

    Study evaluated the effect of ProAir Digihaler System on asthma control versus standard of care as measured by Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versus standard of care.


    Lead Product(s): Salbutamol Sulphate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: ProAir Digihaler

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 29, 2022

    blank

    02

    Assia Chemical Industries Ltd

    Israel
    arrow
    IOPC
    Not Confirmed

    Assia Chemical Industries Ltd

    Israel
    arrow
    IOPC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Salbutamol Sulphate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol...

    Details : Study evaluated the effect of ProAir Digihaler System on asthma control versus standard of care as measured by Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versu...

    Product Name : ProAir Digihaler

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 29, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Assia Chemical Industries Ltd and get a quotation

    Assia Chemical Industries Ltd is a supplier offers 71 products (APIs, Excipients or Intermediates).

    Find a price of Aripiprazole bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Candesartan Cilexetil bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Cilostazol bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Duloxetine Hydrochloride bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Lansoprazole bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Levofloxacin bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Losartan Potassium bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Maxacalcitol bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Modafinil bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Nateglinide bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Paroxetine Hydrochloride bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Risperidone bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Telmisartan bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Zoledronic Acid bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Zolpidem Tartrate bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of ST-ID2498 bulk with JDMF offered by Assia Chemical Industries Ltd

    Find a price of Diclofenac Sodium bulk offered by Assia Chemical Industries Ltd

    Find a price of Nitrofurantoin bulk offered by Assia Chemical Industries Ltd

    Find a price of Nitrofurazone bulk offered by Assia Chemical Industries Ltd

    Find a price of Triamterene bulk offered by Assia Chemical Industries Ltd

    Find a price of FACILITIES AND PERSONNEL IN PETAH TIKVA, ISRAEL bulk offered by Assia Chemical Industries Ltd

    Find a price of Acyclovir bulk offered by Assia Chemical Industries Ltd

    Find a price of Alendronate Sodium bulk offered by Assia Chemical Industries Ltd

    Find a price of Apixaban bulk offered by Assia Chemical Industries Ltd

    Find a price of Aripiprazole bulk offered by Assia Chemical Industries Ltd

    Find a price of Atorvastatin bulk offered by Assia Chemical Industries Ltd

    Find a price of Calcipotriol bulk offered by Assia Chemical Industries Ltd

    Find a price of Calcitriol bulk offered by Assia Chemical Industries Ltd

    Find a price of Carbidopa bulk offered by Assia Chemical Industries Ltd

    Find a price of Carvedilol bulk offered by Assia Chemical Industries Ltd

    Find a price of Carvedilol Phosphate bulk offered by Assia Chemical Industries Ltd

    Find a price of Cinacalcet Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Find a price of Clarithromycin bulk offered by Assia Chemical Industries Ltd

    Find a price of Clopidogrel bulk offered by Assia Chemical Industries Ltd

    Find a price of Darifenacin Hydrobromide bulk offered by Assia Chemical Industries Ltd

    Find a price of Desmopressin Acetate bulk offered by Assia Chemical Industries Ltd

    Find a price of Dorzolamide Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Find a price of Doxcercalciferol bulk offered by Assia Chemical Industries Ltd

    Find a price of Exenatide bulk offered by Assia Chemical Industries Ltd

    Find a price of Fluoxetine Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Find a price of Furosemide bulk offered by Assia Chemical Industries Ltd

    Find a price of Gabapentin bulk offered by Assia Chemical Industries Ltd

    Find a price of Ibandronate Sodium bulk offered by Assia Chemical Industries Ltd

    Find a price of Ibrutinib bulk offered by Assia Chemical Industries Ltd

    Find a price of Icatibant Acetate bulk offered by Assia Chemical Industries Ltd

    Find a price of Irbesartan bulk offered by Assia Chemical Industries Ltd

    Find a price of Lamotrigine bulk offered by Assia Chemical Industries Ltd

    Find a price of Latanoprostene Bunod bulk offered by Assia Chemical Industries Ltd

    Find a price of Linagliptin bulk offered by Assia Chemical Industries Ltd

    Find a price of Losartan Potassium bulk offered by Assia Chemical Industries Ltd

    Find a price of Metoprolol Succinate bulk offered by Assia Chemical Industries Ltd

    Find a price of Metoprolol Tartrate bulk offered by Assia Chemical Industries Ltd

    Find a price of Nefazodone Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Find a price of Octreotide Acetate bulk offered by Assia Chemical Industries Ltd

    Find a price of Olmesartan Medoxomil bulk offered by Assia Chemical Industries Ltd

    Find a price of Paricalcitol bulk offered by Assia Chemical Industries Ltd

    Find a price of Pregabalin bulk offered by Assia Chemical Industries Ltd

    Find a price of Probenecid bulk offered by Assia Chemical Industries Ltd

    Find a price of Ramelteon bulk offered by Assia Chemical Industries Ltd

    Find a price of Rasagiline Mesylate bulk offered by Assia Chemical Industries Ltd

    Find a price of Risedronate Sodium bulk offered by Assia Chemical Industries Ltd

    Find a price of Risperidone bulk offered by Assia Chemical Industries Ltd

    Find a price of Rivaroxaban bulk offered by Assia Chemical Industries Ltd

    Find a price of Rosuvastatin Calcium bulk offered by Assia Chemical Industries Ltd

    Find a price of Sertraline Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Find a price of Tadalafil bulk offered by Assia Chemical Industries Ltd

    Find a price of Terazosin HCl bulk offered by Assia Chemical Industries Ltd

    Find a price of Tigecycline bulk offered by Assia Chemical Industries Ltd

    Find a price of Trazodone Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Find a price of Valacyclovir Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Find a price of Venlafaxine Hydrochloride bulk offered by Assia Chemical Industries Ltd

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search